Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
2018
Purpose To analyse safety and efficacy of treatment based on
ombitasvir/paritaprevir/ritonavir/
dasabuvirplus
ribavirinin the sub-group of GT1 patients older than 65 years.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
21
References
6
Citations
NaN
KQI